Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 06 January, 2004

Xenova Group PLC

Re: Farnham Research Facility

Xenova Group PLC
06 January 2004
                              

                              Xenova Group plc
                 Sale of Farnham Research Facility to Bioventix

Slough, UK, 6 January 2004 - Xenova Group plc (NASDAQ, NY: XNVA, London Stock
Exchange, XEN) today announced that it has sold certain premises at its Farnham
research facility together with related assets to Bioventix Limited ('Bioventix
'). The sale assets constitute part of the business acquired by the Group upon
the acquisition of KS Biomedix Holdings plc.  The consideration for the sale
assets was £0.8m paid in cash.

The sale includes certain rights to intellectual property relating to super
high-affinity antibodies that are not being developed by Xenova, and provides
for the continuation of work by Bioventix on novel three-part proteins ('trimers
') being developed under an option agreement with Isis Innovations Ltd.  Xenova
has retained an option to develop any promising therapeutic candidates arising
from this work. In addition, a team of 7 research scientists is transferring
with the business to Bioventix.

The sale is in line with Xenova's declared strategy following the acquisition of
KS Biomedix Holdings plc on 12 September 2003, of focusing on its clinical
development portfolio and achieving cost savings through the disposal of
non-core business activities and facilities.

Commenting on the disposal, David Oxlade, Chief Executive of Xenova, said, 'We
are pleased to announce continuing progress in achieving the cost savings
expected at the time of the acquisition of KS Biomedix Holdings plc and to
realise value from non-core assets for our shareholders. The sale to Bioventix,
which is being run by Peter Harrison formerly of KS Biomedix, also provides
Xenova an option to in-licence certain therapeutic candidates.'


Contacts:
UK:                                        US:
Xenova Group plc                           Trout Group/BMC Communications
Tel: +44 (0)1753 706600                    Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer    Press: Brad Miles (Ext 17)
Daniel Abrams, Finance Director            Daniel Budwick (Ext 14)
Veronica Cefis Sellar, Corporate           Investors: Jonathan Fassberg (Ext 16)
Communications                             Lee Stern (Ext 22)

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Ben Atwell


Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova has a broad pipeline of
programmes in clinical development.  The Group has a well-established track
record in the identification, development and partnering of innovative products
and technologies and has partnerships with significant pharmaceutical and
biopharmaceutical companies including Celltech, Genentech, Lilly, Millennium
Pharmaceuticals, Nycomed, Pfizer and QLT.

Bioventix Ltd is a company that was formed in order to acquire certain premises
at Xenova's Farnham research facility together with related assets and aims to
develop and commercialise antibodies and antibody fragments and derivatives
initially derived from sheep as diagnostic and therapeutic products.  As a
result, the Company will sell unlabelled sheep antibodies to T3 for diagnostic
use and rights to develop new diagnostic and therapeutic products to other
targets.  (These rights exclude directly and indirectly labelled diagnostic
products to carcino-embryonic antigen (CEA) and directly labelled therapeutic
products to CEA.).  Bioventix will also develop novel trimeric antibody entities
for use in targeting solid tumours.


For further information about Xenova and its products please visit the Xenova
website at www.xenova.co.uk


For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about our ability to
integrate acquired businesses and realize cost savings from integration, and
the discovery, development and commercialization of products. Various risks may
cause Xenova's actual results to differ materially from those expressed or
implied by the forward looking statements, including: unexpected costs and
delays in integrating acquired businesses into our group, adverse results in our
drug discovery and clinical development programs; failure to obtain patent
protection for our discoveries; commercial limitations imposed by patents owned
or controlled by third parties; our dependence upon strategic alliance partners
to develop and commercialize products and services; difficulties or delays in
obtaining regulatory approvals to market products and services resulting from
our development efforts; the requirement for substantial funding to conduct
research and development and to expand commercialization activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.


                      This information is provided by RNS
            The company news service from the London Stock Exchange